Aemetis, Inc $AMTX Shares Sold by Grantham Mayo Van Otterloo & Co. LLC

Key Points

• Grantham Mayo Van Otterloo reduced its Aemetis stake by 39.2% in Q3, selling 652,100 shares and now holding 1,011,412 shares (about 1.54%) valued at roughly $2.28M.
• Analysts show a Moderate Buy consensus (three Buys, one Sell) with an average target of $17.00, while Ascendiant recently cut its target to $20 but maintained a buy rating.
• Aemetis shares trade near $1.57 (12‑month range $1.22–$3.66), with a market cap around $104M and a negative trailing P/E (–0.98), indicating the company is currently loss-making.

Grantham Mayo Van Otterloo & Co. LLC lowered its position in Aemetis, Inc (NASDAQ:AMTX - Free Report) by 39.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,011,412 shares of the specialty chemicals company's stock after selling 652,100 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC owned 1.54% of Aemetis worth $2,276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd purchased a new position in shares of Aemetis in the 2nd quarter worth about $25,000. Creative Planning acquired a new position in shares of Aemetis in the 2nd quarter valued at about $30,000. Engineers Gate Manager LP purchased a new stake in shares of Aemetis during the 2nd quarter worth about $42,000. Tower Research Capital LLC TRC grew its holdings in shares of Aemetis by 206.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 22,962 shares of the specialty chemicals company's stock worth $57,000 after purchasing an additional 15,474 shares during the period. Finally, Jump Financial LLC acquired a new stake in Aemetis during the 2nd quarter worth approximately $64,000. Hedge funds and other institutional investors own 27.02% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AMTX shares. Ascendiant Capital Markets cut their price target on shares of Aemetis from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, November 19th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Aemetis in a research note on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Aemetis currently has an average rating of "Moderate Buy" and an average target price of $17.00.

Aemetis Price Performance

Shares of AMTX opened at $1.57 on Wednesday. Aemetis, Inc has a 12 month low of $1.22 and a 12 month high of $3.66. The stock's 50-day moving average is $1.53 and its two-hundred day moving average is $1.91. The stock has a market cap of $103.93 million, a PE ratio of -0.98 and a beta of 2.61.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.